Welcome to our dedicated page for Heron Therapeutics SEC filings (Ticker: HRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Heron Therapeutics, Inc. (HRTX) SEC filings page provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. As a Nasdaq‑listed commercial-stage biotechnology company, Heron uses Forms 10‑K, 10‑Q, 8‑K, and proxy statements on Schedule 14A to report financial results, material events, and governance matters related to its acute care and oncology supportive care business.
Investors reviewing HRTX SEC filings can examine current reports on Form 8‑K that disclose items such as quarterly and year‑to‑date financial results, capital restructuring transactions, amendments to credit facilities with Hercules Capital, Inc., exchange and issuance of convertible senior unsecured promissory notes, private placements of common and preferred equity, and adoption of a Tax Benefit Preservation Plan intended to protect net operating loss carryforwards. Other 8‑K filings describe material agreements, manufacturing and supply arrangements with Patheon, office lease commitments for corporate headquarters, and changes in the composition of the Board of Directors.
Heron’s proxy statements on Schedule 14A provide detail on stockholder meetings, including special meetings to approve the issuance of common stock upon conversion of convertible notes and Series A Convertible Preferred Stock under Nasdaq Listing Rule 5635(d). These documents explain voting procedures, virtual meeting logistics, and the specific proposals presented to stockholders.
Through this page, users can also track governance and capital structure disclosures such as the creation of Series A Convertible Preferred Stock and Series B Preferred Stock, rights plans, and cooperation agreements with significant investors. Stock Titan enhances these filings with AI‑powered summaries that highlight key terms, financial implications, and governance changes, helping readers quickly understand complex agreements without replacing the full legal text. Real‑time updates from EDGAR ensure that new HRTX filings, including 10‑K annual reports, 10‑Q quarterly reports, and Form 4 insider transaction reports when available, are surfaced promptly for further analysis.
Morgan Adam reported open-market purchase transactions in a Form 4 filing for HRTX. The filing lists transactions totaling 1,836,558 shares at a weighted average price of $2.01 per share. Following the reported transactions, holdings were 70,012 shares.
Heron Therapeutics, Inc. entered into a cooperation agreement with Rubric Capital Management to expand its board from six to seven directors and to include a Rubric-nominated director in the company’s slate for the 2026 annual meeting, together with standstill and mutual non-disparagement provisions. The company also adopted a Certificate of Designation creating 524,141 shares of Series A Convertible Preferred Stock with a stated value of $15.00 per share, convertible at $1.50 per share upon stockholder approval and subject to a beneficial ownership limitation generally set at 4.99% (adjustable up to 19.99%).
The company completed a package of refinancing transactions that restructure its capital: it increased secured term loan capacity to $150.0 million with $110.0 million funded on closing, exchanged $25.0 million of existing convertible notes for 16,666,666 common shares and repaid the remaining $125.0 million of those notes in cash, issued $35.0 million of new convertible notes for $33.25 million, and completed a private placement of 13,225,227 common shares plus the Series A preferred (which converts into 5,241,410 common shares at $1.50) for approximately $27.7 million. These actions materially change the company’s debt profile and equity base.
Heron Therapeutics (HRTX) entered a Framework Agreement with Patheon Austria GmbH & Co KG under which Patheon will manufacture and supply specified quantities of certain products and continue ongoing stability studies and warehousing services. The Company has committed to purchase 38,400 kg of Products through December 31, 2026. The Framework Agreement also terminates certain prior agreements and historical obligations between the parties and amends a previously executed Manufacturing and Supply Agreement to govern ongoing manufacturing and stability-study terms.
The company states the description is summary in nature and plans to file the full Framework Agreement as an exhibit to its Quarterly Report for the fiscal quarter ending September 30, 2025.
Heron Therapeutics (HRTX) Q2-25 10-Q highlights
- Revenue: Net product sales rose 3.3% YoY to $37.2 m; 1H-25 sales up 7.7% to $76.1 m. Growth was driven by Zynrelef (+40% YoY) and Aponvie (+142%), offset by lower Sustol.
- Margins: Q2 gross margin expanded to 73% (prior-year 71%). Operating expenses fell 9% to $29.0 m on lower R&D (-34%) and SG&A (-15%), narrowing the operating loss to $1.6 m from $6.4 m.
- Profitability: Q2 net loss improved to $2.4 m (-$0.02/sh) vs -$9.2 m (-$0.06/sh). For 1H-25 the company posted a small profit of $0.3 m versus a -$12.4 m loss a year earlier.
- Liquidity: Cash & short-term investments were $40.6 m (down from $59.3 m YE-24) after operating cash burn of $19.7 m YTD. Inventory rose $19.8 m to $73.0 m (mainly Cinvanti and Zynrelef).
- Balance sheet: Total debt $175.2 m, comprised of $149.8 m 1.5% senior converts due May-26 and $25.4 m drawn under the Hercules working-capital facility. Stockholders’ deficit improved to -$27.3 m.
- Refinancing plan: On 8-8-25 the company signed agreements to upsize the Hercules facility to $150 m, issue $35 m 5% converts due 2031, sell $29.7 m in equity/Series A preferred, and exchange/repay the existing $150 m converts. Closings expected 8-12-25, eliminating near-term maturities and adding working capital.
Outlook: Management believes current cash plus proceeds from the refinancing will fund operations for ≥12 months. Key drivers remain Zynrelef uptake, successful launch of the vial-access needle, and execution of the Hercules credit milestones.
Heron Therapeutics (HRTX) restructures and adds liquidity via four coordinated transactions dated 8 Aug 25.
Debt amendment: Working Capital Facility with Hercules rises to $150 m (tranche 1 $110 m closing; tranche 2 $20 m available through 15 Dec 26; tranche 3 $20 m by 30 Sep 27). Maturity shifts to the earlier of 1 Sep 30 or 180 days before any new convert maturity. Interest = Prime (7.5 % floor)+1.95 % cash +1.0 % PIK; 1 % upfront fee and up to 6.25 % end-of-term; no amortization.
Convertible clean-up: $150 m 2021 unsecured converts will be exchanged—$25 m converts to common, $125 m plus accrued interest paid in cash—removing a large overhang.
New convert issue: Company to sell $35 m senior unsecured converts (55-month term, 5 % OID, 5 % coupon; 7 % PIK option year 1) convertible at $1.80, subject to shareholder approval.
Private placement: $27.7 m raised via 13.23 m common shares and 0.524 m Series A preferred (auto-converts to 5.24 m common) at $1.50. Proceeds earmarked for working capital. All deals target 12 Aug 25 closing; company will seek shareholder and resale-registration approvals.
Heron Therapeutics, Inc. (HRTX) – Form 4 insider filing
EVP & Chief Development Officer William P. Forbes reported the vesting and automatic conversion of 3,874 restricted stock units (RSUs) into common shares on 07/19/2025 (transaction code “M”). No shares were sold, and the RSUs carried a $0.00 exercise price. Following the conversion, Forbes’ direct common-stock holdings increased to 138,940 shares. He still holds 38,743 unvested RSUs, which continue to vest quarterly through the original 01/19/2028 schedule. No other equity instruments or derivative transactions were disclosed.
- No cash proceeds were generated; the transaction simply moved shares from the derivative column to direct ownership.
- The filing does not indicate any open-market purchases or dispositions, suggesting the move is part of a pre-set equity-compensation plan.
Form 4 filing for Heron Therapeutics, Inc. (HRTX) discloses that Executive Vice President & Chief Financial Officer Ira Duarte converted 3,874 Restricted Stock Units (RSUs) into an equal number of common shares on 07/19/2025 (transaction code M).
Following the conversion, Duarte directly owns 152,523 HRTX common shares and retains 38,743 unvested RSUs. The RSUs originally granted on 01/19/2024 vest in 16 equal quarterly instalments; the reported tranche represents one of these scheduled releases. No shares were sold and no cash price is indicated (exercise price $0), so total insider ownership increased by the same amount as shares acquired.
No other non-derivative or derivative transactions were reported. This appears to be a routine vesting/settlement event rather than an open-market purchase or disposition.